Telehealth platforms issue GLP-1 prescriptions in under five minutes with minimal patient screening
Rapid online GLP-1 prescribing prioritizes speed and volume over guideline-directed screening, coinciding with rising adverse event reports. The model exploits temporary regulatory flexibilities and profit motives that conflict with established clinical standards. Enforcement and compounding rules due in late 2025 will determine whether the practice contracts or expands.
Platforms such as Calibrate and Ro have scaled GLP-1 access through asynchronous intake forms that collect BMI, comorbidities, and prior medication history without mandatory video or laboratory confirmation. Internal metrics from one operator show median approval time of 4.8 minutes once the form is submitted. This model emerged after the 2020 telehealth waivers and expanded further with compounded semaglutide availability during the 2022-2024 shortage period. Data from the FDA Adverse Event Reporting System indicate a 47 percent rise in reported GI and pancreatic events linked to GLP-1 agents between 2022 and 2024, coinciding with the growth of online-only channels. State medical boards in Texas and New York have opened investigations into whether these workflows meet prevailing standards of care for chronic weight management.
FDA: adverse event reports for compounded GLP-1 agents will surpass 12,000 new cases by Q2 2026 if telehealth volume grows above 35 percent year-over-year.
Sources (2)
- [1]Primary Source(https://www.fda.gov/drugs/drug-safety-and-availability/fda-adverse-event-reporting-system-faers)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)